|La Jolla Signs Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb|
|By David Fowler|
|Wednesday, 05 August 2015 18:10|
Leader of innovative therapies, La Jolla Pharmaceutical Company (NASDAQ:LJPC), has confirmed signing of two exclusive worldwide license agreements for intellectual property rights that would include La Jolla’s next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb.The first license agreement is with Indiana University Research and Technology Corporation as well as second with IURTC along with University of Alabama at Birmingham.
The license agreements following the earlier agreements include use of LJPC-30Sa as well as LJPC-30Sb besides potential treatment of rare genetic disorders.
Despite kidney toxicity, gentamicin is now most commonly prescribed hospital antibiotics because of broad spectrum of antimicrobial efficacy. It comprises of mainly a mixture of closely related chemical entities which may aid in product’s toxicity profile. LJPC-30Sb and LJPC-30Saare purified components of presently marketed gentamicin product retaining biologic activity of gentamicin.
La Jolla aims to continue the dual development strategy with the next-generation gentamicin derivative program. The firm mainly aims to develop LJPC-30Sa as well as LJPC-30Sb not just for potential treatment of serious bacterial infections but also for potential treatment of rare genetic disorders like cystic fibrosis along with Duchenne muscular dystrophy.
George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, opined that it is glad by regular progress of next-generation gentamicin derivative program. Tidmarsh added that after a positive pre-IND meeting with FDA, they are looking forward on furthering the program with filing of an IND after start of Phase 1 clinical trial.